The Experts below are selected from a list of 75 Experts worldwide ranked by ideXlab platform
Kikkeri N Naresh - One of the best experts on this subject based on the ideXlab platform.
-
Expression of enhancing factor/phospholipase A_2 in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis
Oncogene, 2003Co-Authors: Rita Mulherkar, Bhakti M Kirtane, Asha Ramchandani, Nirmala P Mansukhani, Sadhana Kannan, Kikkeri N NareshAbstract:Enhancing factor (EF), a growth factor modulator, is the mouse homologue of human secretory group II phospholipase A_2. EF exhibits growth-promoting activity in vitro , in the presence of epidermal growth factor, and also brings about phenotypic transformation of normal cells. In order to ascertain the role of EF in vivo , a human keratin-14 promoter was used to drive the expression of EF ectopically to squamous epithelial cells. The founder mouse and its progeny showed abnormal whiskers and a scaly, beaded tail. In these mice, keratinization pattern of the epidermis was disturbed and parakeratosis and acanthosis were noted. The transgenic mice, TgK14-EF, expressed EF in the suprabasal layers of tail epidermis as well as in the epithelial cells of Hair follicle and sebaceous glands of skin. Expression of EF along with hyperplasia was also observed in other squamous epithelia such as buccal mucosa, tongue and oesophagus. TgK14-EF mice homozygous for the transgene showed delayed and Scanty Hair growth although the mice were healthy and fertile. The hemizygous TgK14-EF mice were sensitive to a two-stage chemical carcinogenesis and developed a higher number of papillomas than their normal littermates over the course of the experiment. The conversion rate of papilloma to carcinoma was two fold higher in the transgenic mice.
-
Expression of enhancing factor/phospholipase A2 in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis.
Oncogene, 2003Co-Authors: Rita Mulherkar, Bhakti M Kirtane, Asha Ramchandani, Nirmala P Mansukhani, Sadhana Kannan, Kikkeri N NareshAbstract:Enhancing factor (EF), a growth factor modulator, is the mouse homologue of human secretory group II phospholipase A2. EF exhibits growth-promoting activity in vitro, in the presence of epidermal growth factor, and also brings about phenotypic transformation of normal cells. In order to ascertain the role of EF in vivo, a human keratin-14 promoter was used to drive the expression of EF ectopically to squamous epithelial cells. The founder mouse and its progeny showed abnormal whiskers and a scaly, beaded tail. In these mice, keratinization pattern of the epidermis was disturbed and parakeratosis and acanthosis were noted. The transgenic mice, TgK14-EF, expressed EF in the suprabasal layers of tail epidermis as well as in the epithelial cells of Hair follicle and sebaceous glands of skin. Expression of EF along with hyperplasia was also observed in other squamous epithelia such as buccal mucosa, tongue and oesophagus. TgK14-EF mice homozygous for the transgene showed delayed and Scanty Hair growth although the mice were healthy and fertile. The hemizygous TgK14-EF mice were sensitive to a two-stage chemical carcinogenesis and developed a higher number of papillomas than their normal littermates over the course of the experiment. The conversion rate of papilloma to carcinoma was two fold higher in the transgenic mice.
Rita Mulherkar - One of the best experts on this subject based on the ideXlab platform.
-
Expression of enhancing factor/phospholipase A_2 in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis
Oncogene, 2003Co-Authors: Rita Mulherkar, Bhakti M Kirtane, Asha Ramchandani, Nirmala P Mansukhani, Sadhana Kannan, Kikkeri N NareshAbstract:Enhancing factor (EF), a growth factor modulator, is the mouse homologue of human secretory group II phospholipase A_2. EF exhibits growth-promoting activity in vitro , in the presence of epidermal growth factor, and also brings about phenotypic transformation of normal cells. In order to ascertain the role of EF in vivo , a human keratin-14 promoter was used to drive the expression of EF ectopically to squamous epithelial cells. The founder mouse and its progeny showed abnormal whiskers and a scaly, beaded tail. In these mice, keratinization pattern of the epidermis was disturbed and parakeratosis and acanthosis were noted. The transgenic mice, TgK14-EF, expressed EF in the suprabasal layers of tail epidermis as well as in the epithelial cells of Hair follicle and sebaceous glands of skin. Expression of EF along with hyperplasia was also observed in other squamous epithelia such as buccal mucosa, tongue and oesophagus. TgK14-EF mice homozygous for the transgene showed delayed and Scanty Hair growth although the mice were healthy and fertile. The hemizygous TgK14-EF mice were sensitive to a two-stage chemical carcinogenesis and developed a higher number of papillomas than their normal littermates over the course of the experiment. The conversion rate of papilloma to carcinoma was two fold higher in the transgenic mice.
-
Expression of enhancing factor/phospholipase A2 in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis.
Oncogene, 2003Co-Authors: Rita Mulherkar, Bhakti M Kirtane, Asha Ramchandani, Nirmala P Mansukhani, Sadhana Kannan, Kikkeri N NareshAbstract:Enhancing factor (EF), a growth factor modulator, is the mouse homologue of human secretory group II phospholipase A2. EF exhibits growth-promoting activity in vitro, in the presence of epidermal growth factor, and also brings about phenotypic transformation of normal cells. In order to ascertain the role of EF in vivo, a human keratin-14 promoter was used to drive the expression of EF ectopically to squamous epithelial cells. The founder mouse and its progeny showed abnormal whiskers and a scaly, beaded tail. In these mice, keratinization pattern of the epidermis was disturbed and parakeratosis and acanthosis were noted. The transgenic mice, TgK14-EF, expressed EF in the suprabasal layers of tail epidermis as well as in the epithelial cells of Hair follicle and sebaceous glands of skin. Expression of EF along with hyperplasia was also observed in other squamous epithelia such as buccal mucosa, tongue and oesophagus. TgK14-EF mice homozygous for the transgene showed delayed and Scanty Hair growth although the mice were healthy and fertile. The hemizygous TgK14-EF mice were sensitive to a two-stage chemical carcinogenesis and developed a higher number of papillomas than their normal littermates over the course of the experiment. The conversion rate of papilloma to carcinoma was two fold higher in the transgenic mice.
Niranjan Khandelwal - One of the best experts on this subject based on the ideXlab platform.
-
clinical profile of children with biotinidase deficiency and response to oral biotin therapy experience from a developing country
13th International Child Neurology Congress (ICNC2014), 2014Co-Authors: Pratibha Singhi, Arushi Gahlot Saini, Puneet Jain, Savita Verma Attri, Renu Suthar, Jitendra Kumar Sahu, Naveen Sankhyan, Niranjan KhandelwalAbstract:Objectives : To study the clinical profile of children with biotinidase deficiency and their response to oral biotin. Methods : Twenty-six consecutive patients with biotinidase deficiency diagnosed from September 2004-November 2013 were retrospectively reviewed. Initiation of biotin treatment was considered early ( 6 months of age); responses were compared. Results : Mean age at symptom-onset was 7.7 months (10 days-48 months). Developmental delay (65%), neuroregression (58%), seizures (81%), skin changes (65%), Scanty Hair (69%) and characteristic rash (31%) were noted at presentation. Generalized tonic-clonic seizures were (61.5%) preponderant. Microcephaly was seen in 35% and hypotonia in 65%. One child had macrocephaly. Perinatal-period was normal in 80%; one child had parental consanguinity. Common electroencephalography abnormalities were generalized spikes/spike-wave-complexes (31%), burst-suppression (15%), focal slowing (11%) and hypsarrhythmia (3%). Common magnetic-resonance-imaging abnormalities were diffuse cortical atrophy (31%), delayed myelination (8%) and non-specific white-matter hyperintensities (8%). Mean serum biotinidase level was 2.28 nmol/min/ml (range 0.08-5 nmol/min/ml). Oral biotin 10-20 mg/day was initiated in all patients; 50% were in early-treatment group. Mean follow-up period was 33.5 months. One patient was vegetative at 9 years of age and two patients died; 77% patients symptomatic relief following biotin therapy. Neurological sequelae noted were intellectual impairment, developmental delay, seizures, hyperactivity and vision-hearing impairments. Poorer seizure control (70% vs 85%), developmental delay (62% vs 70%) and hyperactivity (77% vs 92%) were noted in late vs early-treatment groups respectively. Conclusion : Early recognition and prompt initiation of life-long biotin therapy helps in early seizure control and improved neurological outcomes.
-
Clinical profile of children with biotinidase deficiency and response to oral biotin therapy: Experience from a developing country
2014Co-Authors: Pratibha Singhi, Arushi Gahlot Saini, Puneet Jain, Savita Verma Attri, Renu Suthar, Jitendra Kumar Sahu, Naveen Sankhyan, Niranjan KhandelwalAbstract:Objectives : To study the clinical profile of children with biotinidase deficiency and their response to oral biotin. Methods : Twenty-six consecutive patients with biotinidase deficiency diagnosed from September 2004-November 2013 were retrospectively reviewed. Initiation of biotin treatment was considered early ( 6 months of age); responses were compared. Results : Mean age at symptom-onset was 7.7 months (10 days-48 months). Developmental delay (65%), neuroregression (58%), seizures (81%), skin changes (65%), Scanty Hair (69%) and characteristic rash (31%) were noted at presentation. Generalized tonic-clonic seizures were (61.5%) preponderant. Microcephaly was seen in 35% and hypotonia in 65%. One child had macrocephaly. Perinatal-period was normal in 80%; one child had parental consanguinity. Common electroencephalography abnormalities were generalized spikes/spike-wave-complexes (31%), burst-suppression (15%), focal slowing (11%) and hypsarrhythmia (3%). Common magnetic-resonance-imaging abnormalities were diffuse cortical atrophy (31%), delayed myelination (8%) and non-specific white-matter hyperintensities (8%). Mean serum biotinidase level was 2.28 nmol/min/ml (range 0.08-5 nmol/min/ml). Oral biotin 10-20 mg/day was initiated in all patients; 50% were in early-treatment group. Mean follow-up period was 33.5 months. One patient was vegetative at 9 years of age and two patients died; 77% patients symptomatic relief following biotin therapy. Neurological sequelae noted were intellectual impairment, developmental delay, seizures, hyperactivity and vision-hearing impairments. Poorer seizure control (70% vs 85%), developmental delay (62% vs 70%) and hyperactivity (77% vs 92%) were noted in late vs early-treatment groups respectively. Conclusion : Early recognition and prompt initiation of life-long biotin therapy helps in early seizure control and improved neurological outcomes.
Anil Abraham - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of anti-dandruff activity and safety of polyherbal Hair oil : An open pilot clinical trial Evaluation of anti-dandruff activity and safety of polyherbal Hair oil : An open pilot clinical trial
2004Co-Authors: Chanda Kulkarni, Anil AbrahamAbstract:Dandruff is a common disorder affecting the scalp and can be an embarrassing condition. Currently available treatment options have certain limitations, either due to poor efficacies or due to compliance issues. Furthermore, these drugs are unable to prevent recurrence, which is common troublesome clinical problem. This study was planned to evaluate the clinical efficacy and safety of “Anti-Dandruff Hair Oil” in the management of dandruff. Dandruff is a common disorder affecting the scalp and can be an embarrassing condition. Currently available treatment options have certain limitations, either due to poor efficacies or due to compliance issues. Furthermore, these drugs are unable to prevent recurrence, which is common troublesome clinical problem. This study was planned to evaluate the clinical efficacy and safety of “Anti-Dandruff Hair Oil” in the management of dandruff. ABBREVIATIONS IL : interleukin γ-IFN : gamma-interferon This study was an open, non-comparative, non-randomized, phase III clinical trial, conducted as per the ethical guidelines of Declaration of Helsinki and was approved by Institutional Ethics Committee. Twenty-five patients of both sexes, from the age group of 20-45 years, who were clinically diagnosed as suffering from mild to moderate dandruff, and who were willing to give informed consent were enrolled in the study. Patients with severe Hair fall due to endocrine disorders, patients with Scanty Hair and those with severe scalp skin infection were excluded from the study. All enrolled patients underwent a thorough clinical examination, with special emphasis on local scalp skin examination. All patients were advised to apply 10 ml of “Anti-Dandruff Hair Oil”, twice daily for a period of 2 weeks with gentle massage to the entire scalp and were advised to leave the “Anti-Dandruff Hair Oil” on the scalp for a contact period of minimum 3-4 hours after application. All patients were followed for a period of 2 weeks. Clinical assessment of scalp lesions was done objectively and also subjectively. Thorough scalp examination was done after the completion of 1 week and at the end of the study. The severity of the dandruff symptom was recorded on a score scale and patients, with help of a linear analogue scale, did the subjective assessment. The predefined primary efficacy endpoints were rapid clinical improvement and symptomatic control of dandruff. The predefined secondary safety endpoints for short- and longterm were assessed by incidence of adverse events and patient compliance to the therapy. All adverse events reported or observed by patients were recorded with information about severity, date of onset, duration and action taken regarding the study drug. Statistical analysis was done according to intention-to-treat principles. The minimum level of significance was fixed at 99% confidence limit and a 2-sided p value of
Nirmala P Mansukhani - One of the best experts on this subject based on the ideXlab platform.
-
Expression of enhancing factor/phospholipase A_2 in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis
Oncogene, 2003Co-Authors: Rita Mulherkar, Bhakti M Kirtane, Asha Ramchandani, Nirmala P Mansukhani, Sadhana Kannan, Kikkeri N NareshAbstract:Enhancing factor (EF), a growth factor modulator, is the mouse homologue of human secretory group II phospholipase A_2. EF exhibits growth-promoting activity in vitro , in the presence of epidermal growth factor, and also brings about phenotypic transformation of normal cells. In order to ascertain the role of EF in vivo , a human keratin-14 promoter was used to drive the expression of EF ectopically to squamous epithelial cells. The founder mouse and its progeny showed abnormal whiskers and a scaly, beaded tail. In these mice, keratinization pattern of the epidermis was disturbed and parakeratosis and acanthosis were noted. The transgenic mice, TgK14-EF, expressed EF in the suprabasal layers of tail epidermis as well as in the epithelial cells of Hair follicle and sebaceous glands of skin. Expression of EF along with hyperplasia was also observed in other squamous epithelia such as buccal mucosa, tongue and oesophagus. TgK14-EF mice homozygous for the transgene showed delayed and Scanty Hair growth although the mice were healthy and fertile. The hemizygous TgK14-EF mice were sensitive to a two-stage chemical carcinogenesis and developed a higher number of papillomas than their normal littermates over the course of the experiment. The conversion rate of papilloma to carcinoma was two fold higher in the transgenic mice.
-
Expression of enhancing factor/phospholipase A2 in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis.
Oncogene, 2003Co-Authors: Rita Mulherkar, Bhakti M Kirtane, Asha Ramchandani, Nirmala P Mansukhani, Sadhana Kannan, Kikkeri N NareshAbstract:Enhancing factor (EF), a growth factor modulator, is the mouse homologue of human secretory group II phospholipase A2. EF exhibits growth-promoting activity in vitro, in the presence of epidermal growth factor, and also brings about phenotypic transformation of normal cells. In order to ascertain the role of EF in vivo, a human keratin-14 promoter was used to drive the expression of EF ectopically to squamous epithelial cells. The founder mouse and its progeny showed abnormal whiskers and a scaly, beaded tail. In these mice, keratinization pattern of the epidermis was disturbed and parakeratosis and acanthosis were noted. The transgenic mice, TgK14-EF, expressed EF in the suprabasal layers of tail epidermis as well as in the epithelial cells of Hair follicle and sebaceous glands of skin. Expression of EF along with hyperplasia was also observed in other squamous epithelia such as buccal mucosa, tongue and oesophagus. TgK14-EF mice homozygous for the transgene showed delayed and Scanty Hair growth although the mice were healthy and fertile. The hemizygous TgK14-EF mice were sensitive to a two-stage chemical carcinogenesis and developed a higher number of papillomas than their normal littermates over the course of the experiment. The conversion rate of papilloma to carcinoma was two fold higher in the transgenic mice.
